Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,043 INR | +1.08% |
|
+3.38% | +14.60% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 34.68 and 35.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.60% | 1.7B | D+ | ||
+51.63% | 796B | C+ | ||
+41.51% | 628B | B | ||
-5.10% | 358B | C+ | ||
+19.90% | 331B | B- | ||
+9.95% | 301B | C+ | ||
+17.66% | 244B | B+ | ||
+3.39% | 228B | A+ | ||
+10.75% | 214B | B- | ||
+6.99% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ERIS Stock
- Ratings Eris Lifesciences Limited